News › Industry News, News

Novo Nordisk Reveals Plan to Build Mammoth $4.1B Plant in North Carolina to Help Produce Ozempic, Wegovy

June 28, 2024
Bar graph showing growth

GLP-1 heavyweights Eli Lilly and Novo Nordisk are trading haymakers as they scale up production to meet the overwhelming demand for their revolutionary obesity drugs.

A month after Lilly revealed a $5.3 billion investment to increase its manufacturing capacity, Novo has answered.

On Monday, the Danish drugmaker said it will spend $4.1 billion to construct a second fill-finish plant at its sprawling campus in Clayton, North Carolina. At 1.4 million square feet, the site will match the combined floor space of Novo’s three current manufacturing sites in the state, the company said.

Read more at Fierce Pharma >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics